The document discusses a case study of a pulmonologist who currently prescribes Imipenem for lung infections but does not use Meropenem. The objective is to convince the doctor to prescribe Carnem (Meropenem) instead by highlighting its features, benefits, and superiority over Imipenem. A strategy is outlined to understand the doctor's motives, opinions on Meropenem, and preferred activities. Detailings will focus on Carnem's broad spectrum, newness, penetration abilities, and superior efficacy compared to Imipenem. Activities like trials, presentations, and monitoring are proposed.